The G-BA defines the category other as including diagnostic products used as stress triggers for myocardial perfusion imaging, for example, as well as preparations for the prevention of side effects such as chemotherapy-related nausea and those medicinal products that cannot be assigned to any other group. In this therapeutic area, xx medicinal products have so far been evaluated in XX procedures with a total of xx subpopulations. A major additional benefit has been identified for a weighted xx% of these subpopulations, with a considerable additional benefit for XX%. Proof of a minor additional benefit for XX% of the subpopulations and of a non-quantifiable additional benefit for XX% has been seen.

The G-BA has seen no additional benefit proven for XX% of the subpopulations. This corresponds to xx% of the total xx million patients who fall within the indication areas of the assessed medicinal products and for whom the G-BA therefore sees no proof of additional benefit.